Avadel Pharmaceuticals Stock (NASDAQ: AVDL)

Avadel Pharmaceuticals (NASDAQ:AVDL) Stock

Avadel Pharmaceuticals

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Avadel Pharmaceuticals plc - Ordinary Share

Avadel Pharmaceuticals PLC

WIIM

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

Jasper Therapeutics shares are trading lower after the company reported an 89% response rate in its Urticaria study and will halt the program.

Verticalizes Data Center Ownership to Help Future-Proof Revenue Growth and Enhance Core Profitability
CoreWeave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>), the AI Hyperscaler&#x2122;, and Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>), a leading data center infrastructure provider, today announced that they have signed a definitive agreement under which CoreWeave will acquire Core Scientific in an all-stock transaction. Under the terms of the merger agreement, Core Scientific stockholders will receive 0.1235 newly issued shares of CoreWeave Class A common stock for each share of Core Scientific common stock based on a fixed exchange ratio. Following CoreWeave's successful IPO in March 2025, this acquisition will help CoreWeave verticalize its data center footprint to future-proof revenue growth and enhance profitability. Through this acquisition, CoreWeave will own approximately 1.3 GW of gross power across Core Scientific's national data center footprint1 with an incremental 1 GW+ of potential gross power available for expansion.

Core Scientific, Inc. - Class A Common Stock

CORZ

CRWV

CoreWeave To Acquire Core Scientific In All-Stock Deal To Boost Profitability And Expand Data Center Capacity; Core Scientific Stockholders Will Receive 0.1235 Newly Issued Shares Of CoreWeave Class A Common Stock For Each Share Of Core Scientific Common Stock Based On A Fixed Exchange Ratio

LGPS

LogProstyle shares are trading higher after the company reported a year-over-year increase in FY25 financial results.

Macro Economic Events

News

Politics

Economics

General

U.S. Treasury Secretary Bessent On U.S. Dollar, Says It's Natural For Currencies To Go Up And Down, Not Out Of The Ordinary; Could Mean Other Currencies Are Strengthening; China's Currency Has Also Depreciated; Will Meet With Chinese Counterpart In Next Few Weeks; Are Things For Us To Do Together If China Wants To Do It Beyond Trade

MRNO

Murano Global Investments shares are trading higher after the company announced it entered into a $500 million equity purchase agreement with Yorkville to enhance its Bitcoin treasury strategy.

U.S. Treasury Secretary Bessent Says We Are Going To Have Several Trade Announcements In Next 48 Hours; I Got A Lot Of New Offers Last Night, On Vietnam, Says 20% Overall Tariffs; Trade Letters Are Pretty Standard Letters; On Treasury Or Fed Jobs, Says I Will Do What The President Wants; On Interest Rates, Says Markets May Be Pricing Economic Fundamentals On Possible Rate Cuts

As of July 7, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Apogee Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>)</h3>
<ul class="wp-block-list">
<li>On July 6, Apogee Therapeutics disclosed positive 16-week data from Phase 2 APEX clinical trial of APG777, its potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis. &#8220;With two out of every three patients treated with APG777 achieving EASI-75 response at Week 16 in the Phase 2 APEX Part A trial, APG777 demonstrated the highest EASI-75 response rate both on a topline and placebo-adjusted basis for any biologic in a global study to date, reinforcing its potential best-in-class profile for patients with moderate-to-severe atopic dermatitis,&#8221; said Michael Henderson, M.D., Chief Executive Officer of Apogee. The company's stock jumped around 18% over the past month and has a 52-week high of $63.50.</li>
<li>RSI Value: 84.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>APGE Price Action: Shares of Apogee Therapeutics gained 7.1% to close at $47.46 on Thursday.</li>
<li>Edge Stock Ratings: 70.45 Momentum score </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/apge"><img loading="lazy" decoding="async" width="422" height="183" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07071721/image-59.png" alt="" class="wp-image-974595" style="width:274px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07071721/image-59.png 422w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07071721/image-59-300x130.png 300w" sizes="(max-width: 422px) 100vw, 422px" /></a></figure>
<h3 class="wp-block-heading">Phibro Animal Health Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>)</h3>
<ul class="wp-block-list">
<li>On June 25, Morgan Stanley analyst Erin Wright maintained Phibro Animal Health with an Equal-Weight rating and raised the price target from $21 to $26. The company's stock gained around 16% over the past month and <a href="https://www.benzinga.com/quote/PAHC">has a 52-week high</a> of $28.49.</li>
<li>RSI Value: 81.7</li>
<li>PAHC Price Action: Shares of Phibro Animal Health gained 0.2% to close at $28.00 on Thursday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>.
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

APGE

PAHC

Top 2 Health Care Stocks That May Plunge This Month

JP Morgan analyst Tien-Tsin Huang initiates coverage on Chime Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHYM#NASDAQ">CHYM</a>) with a Overweight rating and announces Price Target of $40.

Price Target

Initiation

Analyst Ratings

CHYM

JP Morgan Initiates Coverage On Chime Financial with Overweight Rating, Announces Price Target of $40

KALV

KalVista Pharmaceuticals shares are trading higher after the company announced it won FDA approval for EKTERLY.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Kaumil Gajrawala upgraded the rating for Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) from Hold to Buy and raised the price target from $194 to $205. Constellation Brands shares closed at $172.32 on Thursday. <a href="https://www.benzinga.com/quote/stz/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Michael Rose upgraded U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) from Outperform to Strong Buy and raised the price target from $51 to $57. U.S. Bancorp shares closed at $47.93 on Thursday. <a href="https://www.benzinga.com/quote/usb/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Julien Dumoulin-Smith upgraded the rating for Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) from Hold to Buy and lifted the price target from&nbsp;$4.9&nbsp;to&nbsp;$7.2. Shoals Technologies shares closed at $5.98 on Thursday. <a href="https://www.benzinga.com/quote/shls/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Ekaterina Knyazkova upgraded Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) from Neutral to Overweight and raised the price target from $25 to $35. Phibro Animal Health shares closed at $28.00 on Thursday. <a href="https://www.benzinga.com/quote/pahc/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying STZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/stz/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07081437/image-63-1024x575.png" alt="" class="wp-image-974676" style="width:607px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07081437/image-63-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07081437/image-63-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07081437/image-63-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07081437/image-63.png 1145w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a> </li>
</ul>
Photo via Shutterstock

Upgrades

OSCR

SHLS

SNDK

VOYG

This Constellation Brands Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

WNS shares are trading higher after announcing that Capgemini will acquire the company for $3.3 billion.

New daily supplement features clinically studied botanicals to support weight loss, healthy fat reduction and energy expenditure&#x2A;
Herbalife Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>), a premier health and wellness company, community and platform, today announced the launch of MultiBurn&#x2122; — a next-generation multi-action dietary supplement designed with clinically studied botanical extracts to support key areas of metabolic health&#x2A;. Formulated by Herbalife's global team of scientists and nutrition experts, MultiBurn&#x2122; is gluten-free, suitable for vegans and made without synthetic colors or dyes, reflecting the company's commitment to clean-label, user-friendly wellness solutions.

Herbalife Unveils MultiBurn, Next-Gen Multi-Action Dietary Supplement, To Support Weight Loss, Healthy Fat Reduction And Energy Expenditure

The shortened week brought central bank heads to Europe, where the European Central Bank hosted its annual forum in Sintra, Portugal. Discussing the topic of macroeconomic shifts and policy responses, Bank of Japan&#8217;s Governor Kazuo Ueda noted that the underlying inflation was slightly below the central bank&#8217;s 2% target.
Clarifying the situation, Ueda pointed to three components that define inflation dynamics—demand-driven price rises, cyclical components such as U.S. tariffs, and domestic supply shocks. Ueda, whose five-year term ends in 2028, said that the much-anticipated additional rate hikes will depend on &#8220;the relative strength of the three dynamics.&#8221;
Meanwhile, his US counterpart, Jerome Powell, drew criticism for a $2.5 billion bill for <a href="https://nypost.com/2025/07/01/opinion/powells-2-5b-fed-revamp-denial-exposes-his-privileged-arrogance/">renovating the central bank&#8217;s Washington headquarters.</a> The work began in 2021, with an estimated cost of $1.9 billion, before costs soared by more than 30%. Multiple parties, including House Judiciary Committee Chair Jim Jordan, have stated that the matter will be investigated. President Donald Trump, who has openly clashed with Powell over the interest rate policy, has called for his resignation. If that were to occur, the impact on the market would be considerable.
While the week ahead is light on news, it also brings Trump&#8217;s tariff deadline of July 9. Thus, market volatility could be considerable.
<h2 class="wp-block-heading">Key News</h2>
<ul class="wp-block-list">
<li>Tuesday: AUD – RBA Interest Rate Decision</li>
<li>Wednesday: NZD – RBNZ Interest Rate Decision, USD – FOMC Meeting Minutes</li>
<li>Thursday: USD – Unemployment Claims</li>
<li>Friday: GBP – GDP m/m, CAD – Unemployment Rate</li>
</ul>
<h2 class="wp-block-heading">Pairs In Focus</h2>
<h3 class="wp-block-heading">&nbsp;1. AUD CAD</h3>
After a two-week surge failed to reach a key weekly level of 0.90100, this pair is reverting toward the lower key level of 0.88750.&nbsp;
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="448" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/07114243/AUDCAD_2025-07-06_19-20-52-1024x448.png" alt="" class="wp-image-15384" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/07114243/AUDCAD_2025-07-06_19-20-52-1024x448.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/07114243/AUDCAD_2025-07-06_19-20-52-300x131.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/07114243/AUDCAD_2025-07-06_19-20-52-768x336.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/07114243/AUDCAD_2025-07-06_19-20-52.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
&nbsp;AUD/CAD daily chart, Source: TradingView
The <a href="https://singaporeforexclub.com/forex-charts-for-beginners">forex chart</a> above shows that a clean break and close on the daily chart would signal a potential run at new lows, with a first stop at support at 0.87850. A rate cut from the Reserve Bank of Australia on Tuesday could be the catalyst for this trade.
<h3 class="wp-block-heading">2. NZD CHF</h3>
The Swiss franc has been one of the best-performing currencies in 2025, owing to its stability and long-standing association with gold. Its advance against the New Zealand dollar has been a multi-month trend, with a prolonged ranging period in May and early June, which has eventually broken to the downside.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="418" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/07114228/NZDCHF_2025-07-06_19-19-54-1024x418.png" alt="" class="wp-image-15383" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/07114228/NZDCHF_2025-07-06_19-19-54-1024x418.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/07114228/NZDCHF_2025-07-06_19-19-54-300x123.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/07114228/NZDCHF_2025-07-06_19-19-54-768x314.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/07114228/NZDCHF_2025-07-06_19-19-54.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
NZD/CHF 4-hour chart, Source: TradingView
Zooming into the H4 chart, any sudden pullbacks above 0.48130, to 0.48300 could be sold with a good price action. The first stop to the downside is around 0.47715, while yearly lows are around 0.46380.
<h3 class="wp-block-heading">Notes:</h3>
<ul class="wp-block-list">
<li>AUD NZD: Ranging around the key level of 1.08180. There is no clear trend, although the bias is slightly bearish.</li>
<li>AUD CHF: Remains in a bearish trend. The pullback has finished in early June, and only a fundamental catalyst could reverse the trend.</li>
<li>AUD JPY:  Price hit a key level at 95.250, but it failed to clearly close above it. As long as that resistance remains in place, the ranging price action can continue.</li>
<li>AUD SGD: Slightly rallied, but failed to make a decisive bullish move. Remains in a range.</li>
<li>CHF JPY:  Reached and exceeded the long-standing 180 target and made a new all-time high—no signs of a pullback.</li>
<li>CAD JPY: Indecisive price action continues. A rally brought it to a 107.05 key level but failed to clear it. A deeper pullback is possible, particularly given the risks associated with tariffs.</li>
<li>EUR AUD: Remains in a bullish trend, and further weakness could propel it towards highs from early April.</li>
<li>EUR/JPY: Pushed to yet another high. A bullish trend could use a breather, but the long-term target, a high from a year ago, is around 175.</li>
<li>EUR NZD: Remains in a strong bullish trend, eyeing the high from early April around 1.99500.</li>
<li>GBP AUD: Overall bullish, but short-term price action is ranging around a key level of 2.08430.</li>
<li>GBP JPY: A pullback has established a potential higher low, meaning that the uptrend might still be in play. The key level above is at 199.700.</li>
<li>GBP NZD: Failed to break higher and surpass a high from May. A key level to observe is 2.25100.</li>
</ul>
Disclaimer: Any opinions expressed in this article are not to be considered investment advice and are solely those of the authors. Singapore Forex Club is not responsible for any financial decisions based on this article's contents. We provide research and promote <a href="https://singaporeforexclub.com/how-to-start-trading-forex-in-singapore" target="_blank" rel="noreferrer noopener">forex trading in Singapore</a>, and readers may use this data for information and educational purposes only.

Forex

Opinion

Tariff Deadline Looms Over The Forex Market

The Live Field Demo with the Company's DefendAir System was Showcased to Senior Israeli Defense Leadership
Kfar Saba, Israel, July 07, 2025 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRZO#NASDAQ">PRZO</a>) (the "company" or "ParaZero"), an aerospace company focused on safety systems for commercial unmanned aerial systems and counter UAS systems, announced the successful completion of a live demonstration of its DefendAir&#x2122; Personal Net Gun System to a select group of Israeli security and defense professionals.
The demonstration was attended by 25 senior officers and experts from various tactical units and critical infrastructure defense entities. During the live field simulation, ParaZero's DefendAir system demonstrated 100% interception success, effectively neutralizing every fast-incoming multirotor drone threat in real-time scenarios. While specific affiliations remain confidential, participants represented top-level Israeli national security sectors, including site protection and strategic defense planning.
The session included an in-depth discussion on the evolving threat of drone incursions, the limitations of existing solutions, and the growing need for multi-layered defense strategies—particularly against passive, non-transmitting drones that cannot be intercepted via traditional RF-based methods, such as fiber-optic-guided drones.
The live field demonstration of the DefendAir Personal Net Gun showcased its ability to rapidly neutralize fast-approaching multirotor drones, simulating a real-time threat scenario. The demonstration generated strong interest and highly positive feedback from attendees.

Global

PRZO

ParaZero Successfully Demos DefendAir Personal Net Gun System To Senior Israeli Defense Officials

JP Morgan analyst Seth Seifman initiates coverage on Voyager Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYG#NYSE">VOYG</a>) with a Overweight rating and announces Price Target of $52.

JP Morgan Initiates Coverage On Voyager Technologies with Overweight Rating, Announces Price Target of $52

Plan Combines Bitcoin Treasury Strategy and Equity Line to Support 2026 Potential Monetization Events, Starting with Pearsanta's Planned IPO

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

ADTX

Aditxt Unveils bitXbio, Its Bitcoin-Backed Treasury Strategy

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Monday.
Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell sharply in today's pre-market trading in response to CEO Elon Musk's re-entry into the political landscape amid his ongoing dispute with President Donald Trump over the <a href="https://www.benzinga.com/markets/tech/25/07/46267743/tesla-shares-fall-over-5-in-overnight-trading-as-elon-musk-jumps-back-into-politics">contentious "Big, Beautiful Bill.</a>"
The decline follows Musk's announcement of the formation of a new political party, in response to the Senate's approval of the "Big, Beautiful Bill." This bill has eliminated the $7500 EV credit and rendered the Zero Emission Vehicle (ZEV) credits, a significant revenue source for Tesla, effectively obsolete.
Tesla shares dipped 6.4% to $295.32 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Bitmine Immersion Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NYSE">BMNR</a>) shares tumbled 19.3% to $110.00 in pre-market trading. BitMine Immersion Technologies shares jumped over 130% on Thursday after the company on Monday announced a $250 million private placement to launch an Ethereum treasury strategy..</li>
<li>Quantum-Si incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) fell 10.3% to $1.92 in pre-market trading after the company announced the pricing of $50 million registered direct offering of common stock.</li>
<li>Webull Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>) declined 9.5% to $12.95 in pre-market trading.</li>
<li>Scage Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCAG#NASDAQ">SCAG</a>) dipped 8.7% to $4.40 in pre-market trading after falling 13% on Thursday.</li>
<li>SK Telecom Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKM#NASDAQ">SKM</a>) declined 6.1% to $22.14 in pre-market trading.</li>
<li>Aebi Schmidt Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEBI#NASDAQ">AEBI</a>) fell 6% to $12.80 in pre-market trading after gaining 22% on Thursday.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) declined 5.8% to $31.99 in pre-market trading after climbing 10% on Thursday.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a> </li>
</ul>
Photo via Shutterstock

Movers

AEBI

BMNR

BULL

SCAG

TSLA

Tesla, Quantum-Si And Other Big Stocks Moving Lower In Monday's Pre-Market Session

As Conagra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) gears up to unveil its fourth-quarter <a href="https://www.benzinga.com/quote/CAG/earnings">earnings on July 10</a>, all eyes are on whether the food giant can maintain its profitability amid shifting market dynamics and a declining revenue forecast—while investors weigh the allure of a tempting dividend yield that could reshape their portfolios.
Analysts expect the company to report quarterly earnings of 61 cents per share, in line with the 61 cents per share reported in the year-ago period. Conagra Brands is projected to report quarterly revenue of $2.88 billion, compared to $2.91 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 2, Morgan Stanley analyst Megan Alexander maintained a Conagra Brands rating of Equal Weight and lowered the price target from $27 to $22.
With the recent buzz around Conagra Brands, some investors may also be eyeing potential gains from the company's dividends. As of now, Conagra Brands offers an annual dividend yield of 6.67%, which is a quarterly dividend amount of 35 cents per share ($1.40 a year).  
So, how can investors capitalize on its dividend yield to earn a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $89,963 or around 4,286 shares. For a more modest $100 per month or $1,200 per year, you would need $17,988 or around 857 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($1.40 in this case). So, $6,000 / $1.40 = 4,286 ($500 per month), and $1,200 / $1.40 = 857 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
CAG Price Action: Shares of Conagra Brands fell 0.7% to close at $20.99 on Thursday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a></li>
</ul>
Photo: Shutterstock

Earnings

Long Ideas

Dividends

How To Earn $500 A Month From Conagra Brands Stock Ahead Of Q4 Earnings

Acquisition strengthens Moog's value proposition for demanding aerospace and defense platforms
Moog Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOG#NYSE">MOG</a>), a worldwide designer, manufacturer and systems integrator of high-performance precision motion and fluid controls and control systems, today announced the acquisition of COTSWORKS Inc., an aerospace and defense fiber optics transceiver component manufacturer, for a purchase price of $63 million. The transaction is subject to customary purchase price adjustments and was paid using a combination of cash and shares of the Company's Class A common stock.
COTSWORKS specializes in designing and manufacturing ruggedized fiber optic transceivers and assemblies used in major aerospace and defense programs across both U.S. and international markets. These mission-critical components deliver high-bandwidth speeds with compact signal density, enabling enhanced digitalization solutions across space, air, land and sea domains.
Moog will expand its existing Space and Defense component portfolio through the integration of COTSWORKS technologies. This acquisition also facilitates the development of next-generation, fully integrated electronics, sensors and data network management solutions. These future products further Moog's customer focus by offering innovative solutions addressing the emerging needs of handling high-bandwidth digital data processing within increasingly compact platforms.

MOG/A

MOG/B

Moog Acquires COTSWORKS For $63M To Boost Aerospace And Defense Fiber Optics Capabilities

Aris Mining Corporation (Aris Mining) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#TSX">ARIS</a>) (NYSE-A: ARMN) and McFarlane Lake Mining Limited (McFarlane) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#CSE">MLM</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MLMLF#OTC">MLMLF</a>) are pleased to announce the signing of a definitive asset purchase agreement (the Agreement) for the sale of Aris Mining's Juby Gold Project and related interests in Ontario, Canada. The total consideration is valued at US$22 million, payable as outlined below.
The Juby Gold Project is an exploration-stage gold project located in the Shining Tree area of Ontario's Abitibi greenstone belt. The transaction includes Aris Mining's 100% interest in the Juby Gold Project and its 25% joint venture interest in the adjacent Knight property.
Under the terms of the Agreement, Aris Mining will receive total consideration of US$22 million, comprised of:
<ul>
<li>US$10 million in cash, payable on closing; &nbsp;</li>
<li>common shares of McFarlane, representing the balance of the consideration payable up to a maximum of 19.9% of its post-financing share capital, issued at the price of McFarlane's concurrent equity financing, and issuable on closing; and &nbsp;</li>
<li>an additional payment, if required to reach the total US$22 million purchase price, payable within 12 months of closing in either cash or additional shares (subject to Aris Mining holding in aggregate no more than 19.9% of McFarlane's share capital), at McFarlane's option.</li>
</ul>
Completion of the transaction is conditional on McFarlane raising at least US$10 million in gross proceeds from a concurrent financing and other customary closing conditions, including required regulatory and third-party approvals, with the transaction expected to close within 90 days. Aris Mining will&nbsp;hold a first-ranking security interest over the Juby Gold Project until full payment of the purchase price is received.

Asset Sales

ARMN

CSE:MLM

MLMLF

TSX:ARIS

Aris Mining And McFarlane Sign Definitive Asset Purchase Agreement For Sale Of Aris Mining's Juby Gold Project And Related Interests In Ontario For $22M

Press Releases

Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Management

Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer

Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Health Care

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Legal

Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation

Comments

Avadel Pharmaceuticals

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL